Gilead reveals positive results for domvanalimab
Study uses carious drug combinations to increase survival among lung cancer patients
Read More
Tag: non-small-cell lung cancer
EQRx receives MHRA marketing approval for sugemalimab
Therapy treats patients with metastatic non-small cell lung cancer and has completed successful phase 3 trial
Read More
Sanofi and Regeneron’s Libtayo trial stops early due to survival improvement
Libtayo plus platinum-doublet chemotherapy led to a 29% reduction in risk of death compared to chemotherapy alone
Read More
Tecentriq wins FDA priority review for certain early NSCLC patients
Tecentriq is first and only cancer immunotherapy with positive Phase III results in adjuvant lung cancer setting
Read More
Novartis’ canakinumab fails to improve overall survival in lung cancer trial
Two additional Phase III trials will continue to investigate canakinumab
Read More
Pfizer’s Lorbrena scores US priority review
Drug is being reviewed for ALK-positive lung cancer
Read More
AZ’s Tagrisso scores priority review from FDA
Agency will review drug for the treatment of early-stage EGFR-mutated lung cancer
Read More
Scancell, CR UK publish joint vaccine update
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Read More
MSD’s Keytruda granted FDA extension
The approval is based on results from the Phase III KEYNOTE-042 trial.
Read More
AZ’ Imfinzi to be funded for NHS use via CDF
AstraZeneca’s PD-L1 inhibitor Imfinzi will be made available on the NHS in England immediately for patients with locally advanced unresectable non-small-cell lung cancer.
Read More
Alunbrig recommended by NICE for non-small-cell lung cancer
NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.
Read More
Early access to Tecentriq combination granted through EAMS
UK patients with a form of advanced lung cancer will soon be able to access the immunotherapy drug Tecentriq in combination with Avastin, carboplatin and paclitaxel through the Early Access to Medicines Scheme (EAMS).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
